ArticleIn vivo (Athens, Greece)
Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting Database.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to identify potential drug associations between proteinuria and nephrotic syndrome (NS) using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND
methodsWe extracted data reported in JADER between April 2004 and May 2023, and conducted a comprehensive disproportionality analysis of spontaneous adverse event reports to identify drugs potentially linked to proteinuria and NS.
resultsOur analysis identified 20 and 32 drugs associated with proteinuria and NS, respectively. Notably, anti-vascular endothelial growth factor (anti-VEGF) agents represented 45% (9/20) of proteinuria-associated drugs and 34% (11/32) of NS-associated drugs. Furthermore, the association between anti-VEGF agents and these adverse events appeared to be independent of the route of administration, sex, or clinical background.
conclusionThese findings suggest that anti-VEGF agents play a significant role in the development of proteinuria and NS. Given the widespread use of anti-VEGF therapy, heightened vigilance, routine monitoring, and timely interventions are crucial to mitigate these risks and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.